Liraglutide add-on to insulin degludec plus metformin vs addition of a single dose of insulin aspart to the largest meal in patients with Type 2 diabetes

被引：0
|
作者：
Russell-Jones, D. [1 ,2 ]
Mathieu, C. [3 ]
Rodbard, H. W. [4 ]
Cariou, B. [5 ]
Handelsman, Y. [6 ]
Philis-Tsimikas, A. [7 ]
Francisco, A. M. Ocampo [8 ]
Rana, A. [8 ]
Zinman, B. [9 ]
机构：
[1] Royal Surrey Cty Hosp, Guildford, Surrey, England
[2] Univ Surrey, Guildford GU2 5XH, Surrey, England
[3] Katholieke Univ Leuven, UZ Gasthuisberg, Louvain, Belgium
[4] Endocrine & Metab Consultants, Rockville, MD USA
[5] CHU Nantes, Inst Thorax, Clin Endocrinol, F-44035 Nantes 01, France
[6] Metab Inst Amer, Tarzana, CA USA
[7] Scripps Hlth, Scripps Whittier Diabet Inst, La Jolla, CA USA
[8] Novo Nordisk AS, Soborg, Denmark
[9] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada
来源：
DIABETIC MEDICINE | 2014年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：52 / 52
页数：1
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC/INSULIN ASPART VERSUS INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES IN CHINA
    Xu, J.
    Lan, K.
    Wang, J.
    VALUE IN HEALTH, 2020, 23 : S111 - S111
  • [42] Efficacy and safety of insulin degludec/insulin aspart vs biphasic insulin aspart 30: an international randomised trial in adults with type 2 diabetes fasting during Ramadan
    Hassanin, M.
    Echtay, A.
    Malek, R.
    Omar, M.
    Shaikh, S.
    Fita, E. G.
    Kaplan, K.
    Kamaruddin, N.
    DIABETOLOGIA, 2017, 60 : S75 - S75
  • [43] Reduced risk of hypoglycaemia with insulin degludec vs insulin glargine in patients with Type 2 diabetes requiring high dose basal insulin
    Gough, S.
    Rodbard, H.
    Handelsman, Y.
    Dykiel, P.
    Lassota, N.
    Lane, W.
    DIABETIC MEDICINE, 2013, 30 : 55 - 55
  • [44] The Efficacy and Safety of Insulin Aspart 30 plus Metformin vs. Insulin Aspart 30 Alone in Treatment for Subjects with Type 2 Diabetes: A Randomized Controlled Trial
    Guo, Lixin, Sr.
    Chen, Li
    Chang, Bao Cheng
    Yang, Li Yong
    Liu, Yu
    Feng, Bo
    DIABETES, 2017, 66 : A255 - A255
  • [45] Insulin Degludec/Liraglutide (Xultophy 100/3.6) for Type 2 Diabetes
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2017, 59 (1529): : 147 - 149
  • [46] EFFECTS OF METFORMIN OR ACARBOSE AS ADD-ON TO INSULIN THERAPY ON GLYCEMIC VARIABILITY IN TYPE 2 DIABETES
    Lu, J.
    Xiaojing, M.
    Lei, Z.
    Yifei, M.
    Lingwen, Y.
    Wei, L.
    Wei, Z.
    Yuqian, B.
    Jian, Z.
    Weiping, J.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2019, 21 : A61 - A62
  • [47] Add-On Treatment with Liraglutide Improves Glycemic Control in Patients with Type 2 Diabetes on Metformin Therapy
    Chiefari, Eusebio
    Capula, Carmelo
    Vero, Ada
    Oliverio, Rosa
    Puccio, Luigi
    Liguori, Rossella
    Pullano, Vittorio
    Greco, Manfredi
    Foti, Daniela
    Tirinato, Domenico
    Vero, Raffaella
    Brunetti, Antonio
    DIABETES TECHNOLOGY & THERAPEUTICS, 2015, 17 (07) : 468 - 474
  • [48] Indirect comparison of efficacy and safety of insulin glargine/lixisenatide and insulin degludec/insulin aspart in type 2 diabetes patients not controlled on basal insulin
    Jammah, Anwar Ali
    PRIMARY CARE DIABETES, 2021, 15 (01) : 132 - 137
  • [49] POSTPRANDIAL DYNAMICS OF PLASMA GLUCOSE, INSULIN, AND GLUCAGON IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN ADD-ON TO METFORMIN THERAPY
    Hansen, Lars
    Iqbal, Nayyar
    Ekholm, Ella
    Cook, William
    Hirshberg, Boaz
    ENDOCRINE PRACTICE, 2014, 20 (11) : 1187 - 1197
  • [50] Insulin aspart in patients with type 2 diabetes
    Fernandez-Garcia, Diego
    Sebastian-Ochoa, Arantzazu
    AVANCES EN DIABETOLOGIA, 2012, 28 : 27 - 31
12345